RedHill Biopharma (RDHL) Assets Average (2013 - 2025)

RedHill Biopharma (RDHL) has 13 years of Assets Average data on file, last reported at $21.9 million in Q4 2025.

• On a quarterly basis, Assets Average rose 9.12% year-over-year to $21.9 million in Q4 2025; TTM through Dec 2025 was $21.9 million, a 9.12% increase from a year earlier, with the FY2025 full-year figure at $21.7 million, up 5.59% from the prior year.
• Assets Average for Q4 2025 stood at $21.9 million, up from $18.2 million in the prior quarter.
• Over the last five years, Assets Average for RDHL reached as high as $211.9 million in Q2 2021 and fell as low as $18.2 million in Q2 2025.
• Historically, Assets Average has averaged $114.7 million across 5 years, with a median of $158.0 million in 2022.
• Across the five-year window, Assets Average soared 84.01% in 2021 and tumbled 81.62% in 2023, its largest moves.
• Year by year, Assets Average stood at $183.8 million in 2021, then retreated by 14.0% to $158.0 million in 2022, then tumbled by 81.62% to $29.0 million in 2023, then tumbled by 31.02% to $20.0 million in 2024, then increased by 9.12% to $21.9 million in 2025.
• Per Business Quant data, the three most recent Assets Average figures were $21.9 million in Q4 2025, $18.2 million in Q2 2025, and $20.0 million in Q4 2024.